Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Exact Sciences's share price for the quarter that ended in Dec. 2023 was $73.98. Exact Sciences's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 181 Mil. Therefore, Exact Sciences's market cap for the quarter that ended in Dec. 2023 was $13,417 Mil.
Exact Sciences's quarterly market cap
declined
from Jun. 2023 ($16,953 Mil) to Sep. 2023 ($12,335 Mil) but then
increased
from Sep. 2023 ($12,335 Mil) to Dec. 2023 ($13,417 Mil).
Exact Sciences's annual market cap
declined
from Dec. 2021 ($13,517 Mil) to Dec. 2022 ($8,809 Mil) but then
increased
from Dec. 2022 ($8,809 Mil) to Dec. 2023 ($13,417 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Exact Sciences's Enterprise Value for Today is $12,597 Mil.
Exact Sciences Market Cap Historical Data
The historical data trend for Exact Sciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Exact Sciences's Market Cap
For the Diagnostics & Research subindustry, Exact Sciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Exact Sciences's Market Cap Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Exact Sciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Exact Sciences's Market Cap falls into.
Exact Sciences Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Exact Sciences's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exact Sciences (NAS:EXAS) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Exact Sciences Market Cap Related Terms
Thank you for viewing the detailed overview of Exact Sciences's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Exact Sciences (Exact Sciences) Business Description
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EXAS has been successfully added to your 